1. A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Issue 12 (22nd September 2020) Authors: Allanore, Yannick; Wung, Peter; Soubrane, Christina; Esperet, Corinne; Marrache, Frederic; Bejuit, Raphael; Lahmar, Amel; Khanna, Dinesh; Denton, Christopher P Journal: Annals of the rheumatic diseases Issue: Volume 79:Issue 12(2020) Page Start: 1600 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗